Psychotropic medicaments comprise a combination of (a) a psychotherapeutic agent and (b) the hypothalamus hormone tripeptide (pyro)-Glu-His-Pro-NH2 (TRH) or its analogue. Joint administration of thymoleptics or mono-aminoxidase inhibitors (which become effective only after administration for 10-20 days) and TRH (the antidepressant effect of which develops rapidly but quickly becomes weaker) potentiates the activity of both components. In the case of neuroleptics, TRH potentiates their antipsychotic activity while reducing their extrapyramidal side-effects. Component (a) can be (i) a thymoleptic, e.g. imipramine, desimipramine, chlorimipramine, amitriptylin, protriptylin, prothiadene, doxepin, nomifensine or mianserin, or aMAO inhibitor, e.g. tranylcypromin, pargylin, phenelzin or nialamide; or (ii) a neuroleptic, e.g. chlorpromazine thioridazine, perphenazine, chlorprothixene, haloperiodol, reserpine, clozapine or sulpiride. Component (b) can be TRH itself, a 1-6C alkylamide of TRH, (pyro)-Glu-His-OH or its (alkyl)amide, (pyro)-Glu-His-pyrolidide. (pyro)-Glu-4-aminobutyric acid, or other derivs. of pyroglutamic acid. e.g. pyrrolidone-N-acetic acid and its amide.
展开▼
